News
anti-VEGF
Anti-VEGF injections may be linked to increased risk of cataracts
Several eye conditions are treated using anti-VEGF injections including retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.
diabetic macular edema
Eylea HD receives approval for dosing interval extension
This updated dosing schedule means that wet AMD and DME patients can now have their treatment plans tailored to their individual needs.
Axpaxli
Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug
Ocular Therpeutix announced successful results of their experimental drug Axpaxli in treating wet age-related macular degeneration.
diabetic macular edema
Eydenzelt receives FDA approval for four retinal diseases
Eydenzelt is approved for use in treating wet age-related macular degeneration, macular edema following reetinal vein occlusion, diabetic macular edema and diabetic retinopathy.
intravitreal injections
Cancer drug may also be a possible treatment for age-related macular degeneration
Clinical trials are set to launch later this year to evaluate whether the cancer drug, PRL3-zumab, is effective in treating wet age-related macular degeneration (AMD) as well as diabetic retinopathy.